This study is looking for people aged 18 to 35 who are experiencing their first episode of psychosis (a mental health condition where a person loses touch with reality). The goal is to see if early treatment with clozapine works better than standard treatments like aripiprazole or risperidone for people who have specific genetic factors. These factors suggest they might not respond well to standard treatments, but also aren't at high risk for certain side effects from clozapine, such as a severe drop in white blood cells (agranulocytosis) or significant weight gain. The main way we'll know if a treatment is successful is by measuring changes in symptoms using a scale called BPRS after 12 weeks. The study is currently recruiting participants.

Study design

This is an interventional study planning to enroll 180 participants. It compares three different drug treatments: aripiprazole, risperidone, and clozapine.

What's involved

To be considered for the study, you would undergo screening that involves an fMRI scan and a blood draw to check for specific biomarkers. If you meet the criteria, you would receive one of the study medications.

Compensation

Not stated in the trial record.

Follow-up

The main symptoms will be measured at 12 weeks after starting treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.